On November 12, 2024, in the wave of rapid growth in pharmaceutical innovation, Hzymes Biotechnology Co., Ltd. (Hzymes) has once again earned a place on the “2024 China Top 100 Life Science Service Companies” list, awarded by the E-Pharma Manager. After being honored in 2023, Hzymes has secured this recognition for a second time, highlighting its exceptional performance in the life science service sector.

E-Pharma Manager,

a professional pharmaceutical industry magazine in China, meticulously selected the top 100 most competitive companies over a three-month period. The selection criteria covered life science service and CXO companies supporting pharmaceutical innovation, with factors such as market valuation and client base. Based on feedback from interviews with executives from 40 companies, the list evaluates brand awareness, cost-effectiveness of collaboration, and service satisfaction, ultimately defining the top 100.

Evaluation Criteria

As a media platform that emphasizes innovation-driven, full-spectrum development of the pharmaceutical industry, E-Pharma Manager evaluated companies over three months. They invited directors of R&D, production, and quality from 40 companies, including Qilu Pharmaceutical and Hengrui Pharmaceuticals, to assess brands across three dimensions: brand awareness (50%), cost-effectiveness of collaboration (30%), and service satisfaction (20%). Factors such as market valuation and client reach were also considered, culminating in the final list.

About Hzymes

Since its founding in 2015, Hzymes has focused on enzyme development innovation, establishing itself as a leader in specialty enzyme research. The company provides high-quality enzyme products for industries like biopharmaceuticals, diagnostic reagents, and biochemical engineering, significantly enhancing product quality and production efficiency across these sectors.
Hzymes has a diversified business layout, covering key areas in life science services. With an annual enzyme production capacity of 1,000 kg, the company meets market demand with large-scale, high-quality production that ensures stability and consistency.

With a cumulative investment of nearly 1 billion RMB and an estimated current valuation of approximately 5 billion RMB, Hzymes has established marketing and R&D centers in Shanghai, Wuhan, and Yichang. The company’s multi-platform, multi-product development strategy has positioned it as a leading supplier of core upstream raw materials for the biopharmaceutical and in vitro diagnostic industries.

Looking ahead, Hzymes is committed to innovation, continually enhancing its capabilities to provide higher-quality, more efficient support for pharmaceutical innovators. The company strives to foster the development of China’s pharmaceutical innovation ecosystem and aims to achieve even greater milestones in the life science service field.